Treating neural disease with tyrosine kinase inhibitors
AssigneeGeorgetown University
InventorCharbel Moussa
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.
Claims53
A method of treating or preventing a neurodegenerative disease, a myodegenerative disease or prion disease in a subject, comprising:
- selecting a subject with a neurodegenerative disease of the central nervous system, a myodegenerative disease, a prion disease or at risk for a neurodegenerative disease of the central nervous system, a myodegenerative disease or a prion disease;
- and
- administering to the subject an effective amount of a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is not Gleevec and wherein the tyrosine kinase inhibitor crosses the blood brain barrier.
A method of inhibiting or preventing toxic protein aggregation in a neuron, a muscle cell or a glial cell, comprising contacting the neuron, the muscle cell or the glial cell with an effective amount of a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is not Gleevec and wherein the tyrosine kinase inhibitor crosses the blood brain barrier.
A method of rescuing a neuron from neurodegeneration, a muscle cell from myodegeneration or a glial cell from degeneration comprising contacting the neuron, the muscle cell or the glial cell with an effective amount of a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is not Gleevec and wherein the tyrosine kinase inhibitor crosses the blood brain barrier.
A method of treating amyotrophic lateral sclerosis or frontotemporal dementia in a subject, comprising:
- selecting a subject with amyotrophic lateral sclerosis or frontotemporal dementia, wherein the subject has a TDP-43 mutation;
- and
- administering to the subject an effective amount of a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is not Gleevec and wherein the tyrosine kinase inhibitor crosses the blood brain barrier.
A method of promoting parkin activity in a subject, comprising:
- selecting a subject with a disorder associated with decreased Parkin activity;
- and
- administering to the subject an effective amount of a small molecule that increase parkin activity, wherein the small molecule is not Gleevec.
A method of treating or preventing a neurodegenerative disease in a subject, comprising:
- selecting a subject with a neurodegenerative disease or at risk for a neurodegenerative disease;
- determining that the subject has a decreased level of parkin activity relative to a control;
- and
- administering to the subject an effective amount of a small molecule that increases parkin activity, wherein the small molecule is not Gleevec.
Dependencies are inferred from the claim text.